Milk Thistle in Liver Diseases: Past, Present, Future

被引:431
作者
Abenavoli, Ludovico [1 ]
Capasso, Raffaele [2 ]
Milic, Natasa [3 ]
Capasso, Francesco [2 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy
[2] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy
[3] Univ Novi Sad, Dept Pharm, Novi Sad 21000, Serbia
关键词
milk thistle; silybin; silipide; silymarin; liver diseases; reactive oxygen species; SILYBIN-PHOSPHATIDYLCHOLINE COMPLEX; NECROSIS-FACTOR-ALPHA; HEPATITIS-C VIRUS; NF-KAPPA-B; DOUBLE-BLIND; MALONDIALDEHYDE LEVELS; SILYMARIN RETARDS; BILIARY FIBROSIS; INSULIN NEED; TNF-ALPHA;
D O I
10.1002/ptr.3207
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Silybum marianum or milk thistle (MT) is the most well-researched plant in the treatment of liver disease. The active complex of MT is a lipophilic extract from the seeds of the plant and is composed of three isomer flavonolignans (silybin, silydianin, and silychristin) collectively known as silymarin. Silybin is a component with the greatest degree of biological activity and makes up 50% to 70% of silymarin. Silymarin is found in the entire plant but it is concentrated in the fruit and seeds. Silymarin acts as an antioxidant by reducing free radical production and lipid peroxidation, has antifibrotic activity and may act as a toxin blockade agent by inhibiting binding of toxins to the hepatocyte cell membrane receptors. In animals, silymarin reduces liver injury caused by acetaminophen, carbon tetrachloride, radiation, iron overload, phenylhydrazine, alcohol, cold ischaemia and Amanita phalloides. Silymarin has been used to treat alcoholic liver disease, acute and chronic viral hepatitis and toxin-induced liver diseases. Copyright (c) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:1423 / 1432
页数:10
相关论文
共 75 条
[31]   Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1(I) and TIMP-1 [J].
Jia, JD ;
Bauer, M ;
Cho, JJ ;
Ruehl, M ;
Milani, S ;
Boigk, G ;
Riecken, EO ;
Schuppan, D .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :392-398
[32]   Silymarin inhibits TNF-α-induced expression of adhesion molecules in human umbilical vein endothelial cells [J].
Kang, JS ;
Park, SK ;
Yang, KH ;
Kim, HM .
FEBS LETTERS, 2003, 550 (1-3) :89-93
[33]   Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages [J].
Kang, JS ;
Jeon, YJ ;
Kim, HM ;
Han, SH ;
Yang, KH .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :138-144
[34]   Cisplatin nephrotoxicity and protection by milk thistle extract in rats [J].
Karimi, G ;
Ramezani, M ;
Tahoonian, Z .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2005, 2 (03) :383-386
[35]   Nuclear factor kappa B: Important transcription factor and therapeutic target [J].
Lee, JI ;
Burckart, GJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (11) :981-993
[36]  
Leng-Peschlow E., 1996, Phytotherapy Research, V10, pS25
[37]   Targeting silibinin in the antiproliferative pathway [J].
Li, Lei ;
Zeng, Jin ;
Gao, Ye ;
He, Dalin .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (02) :243-255
[38]   Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons [J].
Lieber, CS ;
Leo, MA ;
Cao, Q ;
Ren, CL ;
DeCarli, LM .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 37 (04) :336-339
[39]  
LIRUSSI F, 1992, ACTA PHYSIOL HUNG, V80, P363
[40]  
Manna SK, 1999, J IMMUNOL, V163, P6800